Hologic Completes Acquisition of Endomagnetics Ltd
25 Julio 2024 - 7:19AM
Business Wire
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health,
has completed its previously announced acquisition of Endomagnetics
Ltd (Endomag), a privately held UK-based developer of breast cancer
surgery technologies, for approximately $310 million.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240725351417/en/
Endomagnetics breast cancer surgery
technologies (Photo: Business Wire)
“We are thrilled to complete the acquisition of Endomag and are
looking forward to working with our new colleagues to increase
access to their innovative technologies, which complement and
diversify our expanding interventional breast health portfolio,”
said Erik Anderson, President of Breast and Skeletal Health
Solutions at Hologic. “With our shared commitment to advancing
women’s health globally, we are excited to improve outcomes for
patients and, together with our customers, redefine the standard of
care for breast cancer intervention.”
The transaction adds Endomag’s wireless breast surgery
localization and lymphatic tracing solutions – including the
Magseed® marker, the Magtrace® lymphatic tracer and the Sentimag®
platform – to Hologic’s breast surgery portfolio, providing breast
surgeons and radiologists with an expanded range of options and
enhanced user experience.
“We are so proud of the company we built and the
practice-changing breast surgery technologies that we developed
following years of relentless research, innovation and deep
engagement with clinicians,” said Eric Mayes, PhD, Chief Executive
Officer of Endomag. “As we embark on this new journey with Hologic,
I am filled with optimism about the opportunities for our team, our
forthcoming innovations and our ability to impact even more women
around the world.”
About Hologic
Hologic, Inc. is a global leader in women’s health dedicated to
developing innovative medical technologies that effectively detect,
diagnosis and treat health conditions and raise the standard of
care around the world. To learn more, visit www.hologic.com and
connect with us on LinkedIn, Facebook, X (Twitter), Instagram and
YouTube.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about
Hologic’s plans, objectives, expectations and intentions. Such
statements include, without limitation: financial or other
information based upon or otherwise incorporating judgments or
estimates relating to future performance, events or expectations;
strategies, positioning, resources, capabilities, and expectations
for future performance; and financial outlook and other guidance.
These forward-looking statements are based upon assumptions made as
of this date and are subject to known and unknown risks and
uncertainties that could cause actual results to differ materially
from those anticipated.
Risks and uncertainties that could adversely affect Hologic’s
business and prospects, and otherwise cause actual results to
differ materially from those anticipated, include without
limitation: the possibility that the anticipated benefits from the
transaction or products cannot be fully realized or may take longer
to realize than expected; the possibility that costs or
difficulties related to the integration of Endomag operations with
those of Hologic will be greater than expected; the coverage and
reimbursement decisions of third-party payers and the guidelines,
recommendations, and studies published by various organizations
relating to the use of products and treatments; the ability to
successfully manage ongoing organizational and strategic changes,
including Hologic’s ability to attract, motivate and retain key
employees; the development of new competitive technologies and
products; regulatory approvals and clearances for products; the
anticipated development of markets in which products are sold into
and the success of products in these markets; the anticipated
performance and benefits of products; estimated asset and liability
values; anticipated trends relating to Hologic’s financial
condition or results of operations; and Hologic’s capital resources
and the adequacy thereof.
The risks included above are not exhaustive. Other factors that
could adversely affect Hologic’s business and prospects are
described in Hologic’s filings with the SEC. Hologic expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any such statements presented herein to
reflect any change in expectations or any change in events,
conditions or circumstances on which any such statements are
based.
Hologic, The Science of Sure, Magseed, Magtrace and Sentimag are
trademarks and/or registered trademarks of Hologic, Inc. and/or its
subsidiaries in the United States and/or other countries.
Source: Hologic, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725351417/en/
Media Contact Bridget Perry Director, Corporate
Communications (+1) 508.263.8654 bridget.perry@hologic.com
Investor Contact Ryan Simon Vice President, Investor
Relations (+1) 858.410.8514 ryan.simon@hologic.com
Hologic (NASDAQ:HOLX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Hologic (NASDAQ:HOLX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024